Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX3330 in Diabetic Retinopathy
NCT04692688Phase 2Completed
- Sponsor
- Opus Genetics
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic retinopathy (DR) comparing APX3330 with Placebo (2 arms). Primary endpoint: Percent of Subjects With >= 2-step Improvement in Diabetic Retinopathy Severity Score at 24 weeks. Started Apr 2021; status: completed.
02
Drugs
APX3330
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04692688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692688.